IN8BIO (INAB)
IN8BIO on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
33K
Short interest
settlement 2026-10-15
1.0
Days to cover
unchanged vs prior
36.9%
Short share of volume
2026-11-02
607
Fails to deliver
settlement 2026-08-14
Thu 5 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in INAB is 32,797 shares, down 30,313 shares over the last month. Over the last 48 readings it ranged from 9,565 shares (31 October 2025) to 3,762,964 shares (14 February 2025). The latest reading sits at the bottom of that range. At the reported average volume of 46K shares a day that is 1.0 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/inab" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 32,797 | -29.4% | 46,395 | 1.00 |
| 2026-09-30 | 46,440 | -26.4% | 53,488 | 1.00 |
| 2026-09-15 | 63,110 | -30.5% | 28,616 | 2.21 |
| 2026-08-31 | 90,842 | -35.1% | 55,295 | 1.64 |
| 2026-08-14 | 139,903 | +461.6% | 98,439 | 1.42 |
| 2026-07-31 | 24,913 | +19.8% | 55,386 | 1.00 |
| 2026-07-15 | 20,789 | -40.8% | 53,283 | 1.00 |
| 2026-06-30 | 35,117 | -23.5% | 37,497 | 1.00 |
| 2026-06-15 | 45,907 | -57.3% | 55,764 | 1.00 |
| 2026-05-29 | 107,416 | -33.6% | 82,583 | 1.30 |
| 2026-05-15 | 161,813 | -34.1% | 52,250 | 3.10 |
| 2026-04-30 | 245,613 | -29.9% | 71,290 | 3.45 |
| 2026-04-15 | 350,153 | +18.3% | 50,363 | 6.95 |
| 2026-03-31 | 296,110 | +86.0% | 105,659 | 2.80 |
| 2026-03-13 | 159,244 | +14.9% | 40,385 | 3.94 |
| 2026-02-27 | 138,633 | -5.6% | 31,924 | 4.34 |
| 2026-02-13 | 146,831 | +10.0% | 44,619 | 3.29 |
| 2026-01-30 | 133,502 | +13.1% | 81,738 | 1.63 |
| 2026-01-15 | 118,045 | -57.6% | 141,971 | 1.00 |
| 2025-12-31 | 278,120 | +618.2% | 1,147,552 | 1.00 |
| 2025-12-15 | 38,725 | +79.2% | 46,314 | 1.00 |
| 2025-11-28 | 21,609 | -41.9% | 61,961 | 1.00 |
| 2025-11-14 | 37,166 | +288.6% | 82,835 | 1.00 |
| 2025-10-31 | 9,565 | -73.5% | 60,809 | 1.00 |
| 2025-10-15 | 36,093 | -39.0% | 71,889 | 1.00 |
| 2025-09-30 | 59,199 | -9.5% | 85,356 | 1.00 |
| 2025-09-15 | 65,392 | +42.5% | 51,689 | 1.27 |
| 2025-08-29 | 45,893 | -35.7% | 48,952 | 1.00 |
| 2025-08-15 | 71,412 | -35.2% | 94,334 | 1.00 |
| 2025-07-31 | 110,162 | -23.2% | 133,417 | 1.00 |
| 2025-07-15 | 143,446 | -37.4% | 158,356 | 1.00 |
| 2025-06-30 | 229,029 | -5.9% | 163,331 | 1.40 |
| 2025-06-13 | 243,293 | -91.9% | 451,162 | 1.00 |
| 2025-05-30 | 3,015,904 | +143.4% | 9,645,548 | 1.00 |
| 2025-05-15 | 1,239,081 | +190.6% | 2,481,004 | 1.00 |
| 2025-04-30 | 426,329 | -10.9% | 578,348 | 1.00 |
| 2025-04-15 | 478,257 | -52.8% | 733,971 | 1.00 |
| 2025-03-31 | 1,013,407 | -39.3% | 935,066 | 1.08 |
| 2025-03-14 | 1,668,181 | +108.4% | 1,665,930 | 1.00 |
| 2025-02-28 | 800,501 | -78.7% | 2,773,065 | 1.00 |
| 2025-02-14 | 3,762,964 | +768.6% | 26,342,789 | 1.00 |
| 2025-01-31 | 433,213 | -51.9% | 457,176 | 1.00 |
| 2025-01-15 | 899,794 | +86.1% | 1,158,259 | 1.00 |
| 2024-12-31 | 483,592 | -49.8% | 665,089 | 1.00 |
| 2024-12-13 | 963,769 | +12.2% | 1,052,549 | 1.00 |
| 2024-11-29 | 859,263 | -35.7% | 275,238 | 3.12 |
| 2024-11-15 | 1,336,576 | +33.2% | 1,238,253 | 1.08 |
| 2024-10-31 | 1,003,587 | +581.1% | 3,417,246 | 1.00 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of INAB volume is 36.9%, up 24.8 points over the last five sessions. Over the last 30 readings it ranged from 3.3% (16 October 2026) to 75.7% (7 October 2026). The latest reading is 9.9 points above the 30-session average of 27.0%, on 5K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 2K | 5K | 36.9% | 0 |
| 2026-10-30 | 3K | 24K | 10.6% | 0 |
| 2026-10-29 | 207 | 388 | 53.3% | 0 |
| 2026-10-28 | 5K | 9K | 48.1% | 0 |
| 2026-10-27 | 737 | 3K | 24.0% | 153 |
| 2026-10-26 | 13K | 110K | 12.1% | 3,845 |
| 2026-10-23 | 6K | 9K | 69.2% | 900 |
| 2026-10-22 | 8K | 22K | 35.4% | 25 |
| 2026-10-21 | 1K | 28K | 4.4% | 0 |
| 2026-10-20 | 65 | 574 | 11.3% | 0 |
| 2026-10-19 | 3K | 13K | 23.3% | 355 |
| 2026-10-16 | 402 | 12K | 3.3% | 0 |
| 2026-10-15 | 2K | 6K | 31.6% | 0 |
| 2026-10-14 | 6K | 32K | 18.8% | 0 |
| 2026-10-13 | 4K | 36K | 12.4% | 0 |
| 2026-10-12 | 2K | 23K | 6.5% | 0 |
| 2026-10-09 | 271 | 6K | 4.3% | 0 |
| 2026-10-08 | 999 | 16K | 6.1% | 0 |
| 2026-10-07 | 11K | 14K | 75.7% | 0 |
| 2026-10-06 | 18K | 33K | 55.0% | 0 |
| 2026-10-05 | 34K | 66K | 51.0% | 0 |
| 2026-10-02 | 9K | 25K | 33.7% | 0 |
| 2026-10-01 | 14K | 38K | 36.1% | 0 |
| 2026-09-30 | 4K | 15K | 28.2% | 0 |
| 2026-09-29 | 4K | 26K | 15.8% | 0 |
| 2026-09-28 | 9K | 40K | 22.7% | 0 |
| 2026-09-25 | 12K | 35K | 33.6% | 0 |
| 2026-09-24 | 25K | 116K | 21.4% | 0 |
| 2026-09-23 | 1K | 17K | 6.0% | 0 |
| 2026-09-22 | 5K | 24K | 19.5% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 August 2026, the fails-to-deliver balance in INAB is 607 shares, down 6,925 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (17 December 2025) to 172,647 shares (22 December 2025). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-08-14 | 607 | $1.18 | $716 |
| 2026-04-24 | 7,532 | $1.42 | $11K |
| 2026-04-23 | 5,990 | $1.50 | $9K |
| 2026-04-22 | 12,597 | $1.48 | $19K |
| 2026-04-20 | 1,549 | $1.44 | $2K |
| 2026-04-15 | 5 | $1.38 | $7 |
| 2026-04-09 | 8,000 | $1.45 | $12K |
| 2026-03-27 | 410 | $1.47 | $603 |
| 2026-03-11 | 2,055 | $1.81 | $4K |
| 2026-03-10 | 2,111 | $1.81 | $4K |
| 2026-03-02 | 167 | $1.72 | $287 |
| 2026-02-27 | 6 | $1.71 | $10 |
| 2026-02-06 | 1,753 | $1.90 | $3K |
| 2026-02-05 | 174 | $1.96 | $341 |
| 2026-01-29 | 9 | $1.96 | $18 |
| 2026-01-27 | 1 | $2.20 | $2 |
| 2026-01-21 | 228 | $2.36 | $538 |
| 2026-01-20 | 5,403 | $2.59 | $14K |
| 2026-01-16 | 2,330 | $2.32 | $5K |
| 2026-01-15 | 10,602 | $2.21 | $23K |
| 2026-01-14 | 11,653 | $2.17 | $25K |
| 2025-12-29 | 6,278 | $2.23 | $14K |
| 2025-12-26 | 14,869 | $1.99 | $30K |
| 2025-12-24 | 6,560 | $1.75 | $11K |
| 2025-12-23 | 5,000 | $1.55 | $8K |
| 2025-12-22 | 172,647 | $1.21 | $209K |
| 2025-12-19 | 97 | $1.38 | $134 |
| 2025-12-17 | 1 | $1.50 | $2 |
| 2025-12-15 | 790 | $1.68 | $1K |
| 2025-12-12 | 550 | $1.73 | $952 |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for INAB in the last 90 days. The most recent filings are listed below. Latest filing: FAIRBAIRN EMILY (Director) on 2026-05-27.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-05-27 | FAIRBAIRN EMILY | Director | Gift | 725K | $0.00 | $0 | 0 |
| 2025-12-22 | Rochlin Kate | Chief Operating Officer | Grant | 7K | $1.38 | $10K | 9K |
| 2025-12-22 | McCall Patrick | CHIEF FINANCIAL OFFICER | Grant | 7K | $1.38 | $10K | 9K |
| 2025-12-22 | Roemer Alan S. | Director | Grant | 36K | $1.38 | $50K | 50K |
| 2025-12-22 | Ho William Tai-Wei | PRESIDENT AND CEO | Grant | 36K | $1.38 | $50K | 121K |
| 2025-12-22 | FAIRBAIRN EMILY | Director | Grant | 725K | $1.38 | $1000K | 725K |
| 2025-12-22 | Brandt Peter C. | Director | Grant | 72K | $1.38 | $100K | 95K |
| 2025-04-30 | Brandt Peter C. | Director | Exercise or conversion | 82K | $0.18 | $15K | 682K |
| 2025-04-30 | Brandt Peter C. | Director | Exercise or conversion | 82K | $0.18 | $15K | 600K |
| 2025-04-30 | Roemer Alan S. | Director | Exercise or conversion | 102K | $0.18 | $18K | 387K |
| 2025-04-30 | Roemer Alan S. | Director | Exercise or conversion | 11K | $0.18 | $2K | 398K |
| 2025-04-30 | McCall Patrick | CHIEF FINANCIAL OFFICER | Exercise or conversion | 15K | $0.18 | $3K | 67K |
| 2025-04-30 | Rochlin Kate | Chief Operating Officer | Exercise or conversion | 12K | $0.18 | $2K | 55K |
| 2024-10-04 | Ho William Tai-Wei | PRESIDENT AND CEO | Grant | 127K | price not stated in the filing | not stated | 2.5M |
| 2024-10-04 | Brandt Peter C. | Director | Grant | 253K | price not stated in the filing | not stated | 518K |
| 2024-10-04 | Roemer Alan S. | Director | Grant | 127K | price not stated in the filing | not stated | 285K |
| 2024-10-04 | McCall Patrick | CHIEF FINANCIAL OFFICER | Grant | 25K | price not stated in the filing | not stated | 52K |
| 2024-10-04 | Rochlin Kate | Chief Operating Officer | Grant | 25K | price not stated in the filing | not stated | 43K |
| 2023-12-13 | Brandt Peter C. | Director | Grant | 82K | price not stated in the filing | not stated | 264K |
| 2023-12-13 | Lamb Lawrence | EVP and CSO | Grant | 2K | price not stated in the filing | not stated | 101K |
| 2023-12-13 | Goswami Trishna | Chief Medical Officer | Grant | 4K | price not stated in the filing | not stated | 7K |
| 2023-12-13 | Rochlin Kate | Chief Operating Officer | Grant | 12K | price not stated in the filing | not stated | 18K |
| 2023-12-13 | McCall Patrick | Chief Financial Officer | Grant | 20K | price not stated in the filing | not stated | 27K |
| 2023-12-13 | Ho William Tai-Wei | President and CEO | Grant | 82K | price not stated in the filing | not stated | 2.4M |
| 2023-12-13 | Roemer Alan S. | Director | Grant | 102K | price not stated in the filing | not stated | 158K |
| 2023-12-13 | Epperly Corinne | Director | Grant | 82K | price not stated in the filing | not stated | 82K |
| 2023-12-13 | Graff Jeremy R. | Director | Grant | 2K | price not stated in the filing | not stated | 5K |
| 2023-09-13 | Graff Jeremy R. | Director | Buy | 3K | $0.95 | $2K | 3K |
| 2023-08-25 | McCall Patrick | Chief Financial Officer | Buy | 1K | $1.03 | $1K | 6K |
| 2023-08-24 | Ho William Tai-Wei | President and CEO | Buy | 24K | $1.05 | $25K | 2.3M |
| 2023-07-28 | FAIRBAIRN EMILY | Director | Other transaction | 4.1M | $0.00 | $0 | 0 |
| 2022-12-12 | BIOS Fund III QP, LP | Director,TenPercentOwner | Buy | 9K | $2.48 | $22K | 571K |
| 2022-12-12 | BIOS Fund III QP, LP | Director,TenPercentOwner | Buy | 9K | $2.48 | $23K | 602K |
| 2022-12-12 | BIOS Fund III QP, LP | Director,TenPercentOwner | Buy | 57K | $2.48 | $141K | 3.7M |
| 2022-12-12 | Kreis Leslie W. | Director,TenPercentOwner | Buy | 9K | $2.48 | $22K | 571K |
| 2022-12-12 | Kreis Leslie W. | Director,TenPercentOwner | Buy | 9K | $2.48 | $23K | 602K |
| 2022-12-12 | Kreis Leslie W. | Director,TenPercentOwner | Buy | 57K | $2.48 | $141K | 3.7M |
| 2022-09-28 | Bios Equity Partners II, LP | Director,TenPercentOwner | Buy | 3K | $2.02 | $6K | 562K |
| 2022-09-28 | Bios Equity Partners II, LP | Director,TenPercentOwner | Buy | 19K | $2.02 | $38K | 3.7M |
| 2022-09-28 | Bios Equity Partners II, LP | Director,TenPercentOwner | Buy | 3K | $2.02 | $6K | 593K |
| 2022-09-28 | BIOS Fund II NT, LP | Director,TenPercentOwner | Buy | 3K | $2.02 | $6K | 562K |
| 2022-09-28 | BIOS Fund II NT, LP | Director,TenPercentOwner | Buy | 19K | $2.02 | $38K | 3.7M |
| 2022-09-28 | BIOS Fund II NT, LP | Director,TenPercentOwner | Buy | 3K | $2.02 | $6K | 593K |
| 2022-08-29 | Cavu Advisors, LLC | Director,TenPercentOwner | Buy | 5K | $2.02 | $9K | 559K |
| 2022-08-29 | Cavu Advisors, LLC | Director,TenPercentOwner | Buy | 5K | $2.02 | $10K | 590K |
| 2022-08-29 | Cavu Advisors, LLC | Director,TenPercentOwner | Buy | 30K | $2.02 | $61K | 3.7M |
| 2022-08-29 | BIOS Fund II QP, LP | Director,TenPercentOwner | Buy | 5K | $2.02 | $9K | 559K |
| 2022-08-29 | BIOS Fund II QP, LP | Director,TenPercentOwner | Buy | 5K | $2.02 | $10K | 590K |
| 2022-08-29 | BIOS Fund II QP, LP | Director,TenPercentOwner | Buy | 30K | $2.02 | $61K | 3.7M |
| 2022-08-26 | Cavu Advisors, LLC | Director,TenPercentOwner | Buy | 1K | $2.01 | $3K | 585K |
| 2022-08-26 | Cavu Advisors, LLC | Director,TenPercentOwner | Buy | 9K | $2.01 | $17K | 3.6M |
| 2022-08-26 | Cavu Advisors, LLC | Director,TenPercentOwner | Buy | 1K | $2.01 | $3K | 554K |
| 2022-08-26 | BIOS Fund II QP, LP | Director,TenPercentOwner | Buy | 1K | $2.01 | $3K | 585K |
| 2022-08-26 | BIOS Fund II QP, LP | Director,TenPercentOwner | Buy | 9K | $2.01 | $17K | 3.6M |
| 2022-08-26 | BIOS Fund II QP, LP | Director,TenPercentOwner | Buy | 1K | $2.01 | $3K | 554K |
| 2022-08-17 | Cavu Management, LP | Director,TenPercentOwner | Buy | 38K | $1.93 | $73K | 3.6M |
| 2022-08-17 | Cavu Management, LP | Director,TenPercentOwner | Buy | 6K | $1.93 | $11K | 553K |
| 2022-08-17 | Cavu Management, LP | Director,TenPercentOwner | Buy | 6K | $1.93 | $12K | 583K |
| 2022-08-17 | BIOS Fund II NT, LP | Director,TenPercentOwner | Buy | 6K | $1.93 | $11K | 553K |
| 2022-08-17 | BIOS Fund II NT, LP | Director,TenPercentOwner | Buy | 38K | $1.93 | $73K | 3.6M |
| 2022-08-17 | BIOS Fund II NT, LP | Director,TenPercentOwner | Buy | 6K | $1.93 | $12K | 583K |
| 2022-08-16 | BIOS Advisors GP, LLC | Director,TenPercentOwner | Buy | 207K | $1.90 | $392K | 540K |
| 2022-08-16 | BIOS Advisors GP, LLC | Director,TenPercentOwner | Buy | 218K | $1.90 | $414K | 218K |
| 2022-08-16 | BIOS Advisors GP, LLC | Director,TenPercentOwner | Buy | 1.3M | $1.90 | $2.6M | 3.6M |
| 2022-08-16 | BIOS Fund II, LP | Director,TenPercentOwner | Buy | 207K | $1.90 | $392K | 540K |
| 2022-08-16 | BIOS Fund II, LP | Director,TenPercentOwner | Buy | 1.3M | $1.90 | $2.6M | 3.6M |
| 2022-08-16 | BIOS Fund II, LP | Director,TenPercentOwner | Buy | 218K | $1.90 | $414K | 218K |
| 2022-08-16 | Brandt Peter C. | Director | Buy | 105K | $1.90 | $200K | 182K |
| 2022-08-16 | Roemer Alan S. | Director | Buy | 26K | $1.90 | $50K | 56K |
| 2022-08-16 | Greenwood Luba | Director | Buy | 526 | $1.90 | $999 | 8K |
| 2022-08-16 | Lamb Lawrence | EVP and CSO | Buy | 526 | $1.90 | $999 | 100K |
| 2022-08-16 | Goswami Trishna | Chief Medical Officer | Buy | 3K | $1.90 | $5K | 3K |
| 2022-08-16 | McCall Patrick | Chief Financial Officer | Buy | 5K | $1.90 | $10K | 5K |
| 2022-08-16 | Rochlin Kate | Chief Operating Officer | Buy | 5K | $1.90 | $10K | 5K |
| 2022-08-16 | Ho William Tai-Wei | President, CEO and CFO | Buy | 26K | $1.90 | $50K | 2.3M |
| 2022-08-16 | Transcend Partners Opportunity Fund LLC | TenPercentOwner | Buy | 789K | $1.90 | $1.5M | 4.1M |
| 2022-05-05 | Lamb Lawrence | EVP and CSO | Exercise or conversion | 26K | $1.07 | $28K | 99K |
| 2021-08-03 | Transcend Partners Opportunity Fund LLC | TenPercentOwner | Conversion | 28K | price not stated in the filing | not stated | 28K |
| 2021-08-03 | Transcend Partners Opportunity Fund LLC | TenPercentOwner | Conversion | 83K | price not stated in the filing | not stated | 91K |
| 2021-08-03 | Transcend Partners Opportunity Fund LLC | TenPercentOwner | Conversion | 3.2M | price not stated in the filing | not stated | 3.2M |
| 2021-08-03 | Transcend Partners Opportunity Fund LLC | TenPercentOwner | Buy | 100K | $10.00 | $1.0M | 3.3M |
| 2021-08-03 | BIOS Capital Management, LP | TenPercentOwner | Conversion | 359K | price not stated in the filing | not stated | 359K |
| 2021-08-03 | BIOS Capital Management, LP | TenPercentOwner | Conversion | 2.2M | price not stated in the filing | not stated | 2.2M |
| 2021-08-03 | BIOS Capital Management, LP | TenPercentOwner | Conversion | 1.9M | price not stated in the filing | not stated | 1.9M |
| 2021-08-03 | BIOS Capital Management, LP | TenPercentOwner | Conversion | 251K | price not stated in the filing | not stated | 251K |
| 2021-08-03 | BIOS Capital Management, LP | TenPercentOwner | Conversion | 997K | price not stated in the filing | not stated | 997K |
| 2021-08-03 | BIOS Capital Management, LP | TenPercentOwner | Conversion | 341K | price not stated in the filing | not stated | 341K |
| 2021-08-03 | BIOS Capital Management, LP | TenPercentOwner | Conversion | 574K | price not stated in the filing | not stated | 574K |
| 2021-08-03 | Ho William Tai-Wei | President, CEO and CFO | Conversion | 3K | price not stated in the filing | not stated | 73K |
| 2021-08-03 | BIOS Fund II NT, LP | TenPercentOwner | Conversion | 1.9M | price not stated in the filing | not stated | 1.9M |
| 2021-08-03 | BIOS Fund II NT, LP | TenPercentOwner | Conversion | 359K | price not stated in the filing | not stated | 359K |
| 2021-08-03 | BIOS Fund II NT, LP | TenPercentOwner | Conversion | 251K | price not stated in the filing | not stated | 251K |
| 2021-08-03 | BIOS Fund II NT, LP | TenPercentOwner | Conversion | 997K | price not stated in the filing | not stated | 997K |
| 2021-08-03 | BIOS Fund II NT, LP | TenPercentOwner | Conversion | 341K | price not stated in the filing | not stated | 341K |
| 2021-08-03 | BIOS Fund II NT, LP | TenPercentOwner | Conversion | 2.2M | price not stated in the filing | not stated | 2.2M |
| 2021-08-03 | BIOS Fund II NT, LP | TenPercentOwner | Conversion | 574K | price not stated in the filing | not stated | 574K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON14 holders report 5% or more of INAB in their latest filing, all on Schedule 13G (passive). The largest reported stake is LYTTON-KAMBARA FOUNDATION at 10.0% of the class (1,056,513 shares), filed 2026-08-13 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-13 | 13G/Ano. 1 | LYTTON-KAMBARA FOUNDATIONindividual | 1.1M | 10.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 1 | LYTTON LAURENCE Windividual | 1.1M | 10.0% | 2026-06-30 |
| 2026-05-29 | 13D/Ano. 1 | EMILY FAIRBAIRNindividual | 215K | 2.2% | 2026-05-27 |
| 2026-05-29 | 13D/Ano. 1 | Malcom Fairbairnindividual | 206K | 2.1% | 2026-05-27 |
| 2026-05-29 | 13D/Ano. 1 | Malcom and Emily Fairbairn 2010 CRUTother entity | 203K | 2.1% | 2026-05-27 |
| 2026-02-17 | 13G | Alyeska Fund GP, LLCother entity | 966K | 9.9% | 2025-12-31 |
| 2026-02-17 | 13G | Alyeska Investment Group, L.P.investment adviser | 966K | 9.9% | 2025-12-31 |
| 2026-02-17 | 13G | Anand Parekhindividual | 966K | 9.9% | 2025-12-31 |
| 2026-01-29 | 13G | Franklin Advisers, Inc.investment adviser, corporation | 915K | 9.4% | 2025-12-31 |
| 2026-01-29 | 13G | Franklin Resources, Inc.parent holding company, corporation | 915K | 9.4% | 2025-12-31 |
| 2026-01-29 | 13G | Rupert H. Johnson, Jr.parent holding company, individual | 0 | 0.0% | 2025-12-31 |
| 2026-01-29 | 13G | Charles B. Johnsonparent holding company, individual | 0 | 0.0% | 2025-12-31 |
| 2025-12-30 | 13G | Ari Zweimanindividual | 770K | 7.9% | 2025-12-22 |
| 2025-12-30 | 13G | 683 Capital Management, LLCinvestment adviser | 770K | 7.9% | 2025-12-22 |
| 2025-12-30 | 13G | 683 Capital Partners, LPpartnership | 770K | 7.9% | 2025-12-22 |
| 2025-12-29 | 13D/Ano. 4 | BIOS Advisors GP, LLCpartnership | 391K | 4.0% | 2025-12-22 |
| 2025-12-29 | 13D/Ano. 4 | Fletcher Aaron G.L.partnership | 391K | 4.0% | 2025-12-22 |
| 2025-12-29 | 13D/Ano. 4 | BIOS Capital Management, LPpartnership | 391K | 4.0% | 2025-12-22 |
| 2025-12-29 | 13D/Ano. 4 | Cavu Management, LPpartnership | 287K | 2.9% | 2025-12-22 |
| 2025-12-29 | 13D/Ano. 4 | Cavu Advisors, LLCpartnership | 287K | 2.9% | 2025-12-22 |
| 2025-12-29 | 13D/Ano. 4 | Kreis Leslie W.individual | 287K | 2.9% | 2025-12-22 |
| 2025-12-29 | 13D/Ano. 4 | BIOS Equity Partners III, LPpartnership | 163K | 1.7% | 2025-12-22 |
| 2025-12-29 | 13D/Ano. 4 | BIOS Fund III QP, LPpartnership | 124K | 1.3% | 2025-12-22 |
| 2025-12-29 | 13D/Ano. 4 | Bios Equity Partners II, LPpartnership | 123K | 1.3% | 2025-12-22 |
| 2025-12-29 | 13D/Ano. 4 | Bios Clinical Opportunity Fund, LPpartnership | 105K | 1.1% | 2025-12-22 |
| 2025-12-29 | 13D/Ano. 4 | Bios Equity COF, LPpartnership | 105K | 1.1% | 2025-12-22 |
| 2025-12-29 | 13D/Ano. 4 | BIOS Fund II QP, LPpartnership | 63K | 0.6% | 2025-12-22 |
| 2025-12-29 | 13D/Ano. 4 | BIOS Incysus Co-Invest I, LPpartnership | 33K | 0.3% | 2025-12-22 |
| 2025-12-29 | 13D/Ano. 4 | BIOS Fund II, LPpartnership | 19K | 0.2% | 2025-12-22 |
| 2025-12-29 | 13D/Ano. 4 | BIOS Fund III, LPpartnership | 19K | 0.2% | 2025-12-22 |
| 2025-12-29 | 13D/Ano. 4 | BIOS Fund III NT, LPpartnership | 20K | 0.2% | 2025-12-22 |
| 2025-12-29 | 13D/Ano. 4 | BIOS Fund II NT, LPpartnership | 8K | 0.1% | 2025-12-22 |
| 2025-12-29 | 13D/Ano. 4 | Bios Equity Partners, LPpartnership | 0 | 0.0% | 2025-12-22 |
| 2025-12-29 | 13D/Ano. 4 | BP Directors, LPpartnership | 0 | 0.0% | 2025-12-22 |
| 2025-12-22 | 13G | Stonepine Capital Management, LLCinvestment adviser, other entity | 1.0M | 9.9% | 2025-12-19 |
| 2025-12-22 | 13G | Stonepine Capital, L.P.partnership | 1.0M | 9.9% | 2025-12-19 |
| 2025-12-22 | 13G | Stonepine GP, LLCother entity | 1.0M | 9.9% | 2025-12-19 |
| 2025-12-22 | 13G | Jon M. Plexicoparent holding company, individual | 1.0M | 9.9% | 2025-12-19 |
13F holders
Tracked managers holding INAB at their latest 13F. JSON2 of the 30 tracked managers held INAB at their latest 13F, $106K in total at quarter-end prices. Citadel Advisors is the largest at $89K (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 0 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Citadel Advisors | 2026-06-30 | 63K | $89K | 0.00% | new |
| Renaissance Technologies | 2026-06-30 | 12K | $17K | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
IN8BIO in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows IN8BIO (INAB), SEC CIK 1740279, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-08-14.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-13.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-05-27.JSON and CSV
- Company record
- EDGAR filing index for CIK 1740279Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of INAB is sold short?
32,797 shares were held short at the 2026-10-15 settlement, 1.0 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is INAB's daily short volume?
On 2026-11-02, 1,843 of the 4,996 INAB shares reported to FINRA were sold short, 36.9% of the day's reported volume. Short volume is a flow for one day, not a position.
Does INAB have fails to deliver?
The SEC's latest file shows 607 INAB shares failed to deliver at settlement 2026-08-14. Fails are reported per settlement date and published twice a month with a lag.
Are INAB insiders buying or selling?
No open-market insider trades were reported for INAB in the last 90 days. The most recent filings are listed below. Latest filing: FAIRBAIRN EMILY (Director) on 2026-05-27.
Who owns 5% or more of INAB?
14 holders report 5% or more of INAB in their latest filing, all on Schedule 13G (passive). The largest reported stake is LYTTON-KAMBARA FOUNDATION at 10.0% of the class (1,056,513 shares), filed 2026-08-13 for an event on 2026-06-30.
Which tracked 13F managers own INAB?
2 of the 30 tracked 13F managers held INAB shares at their latest filing, $106K in all. The largest: Ken Griffin's Citadel Advisors (63K shares, $89K), Renaissance Technologies (12K shares, $17K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.